chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Extreme soreness in arm and shoulder. Extreme difficulty in movement of arm  e.g. when dressing/undressing. Strong pain and discomfort when sleeping. Pain peaked a few days after vaccination. Slowly subsiding; however still quite relevant after 12 days, and some rotational movement of arms are not feasible yet. Treated with painkiller.
Pain, nerves in chest and breast area damaged and has moved to the right side of the body.  Nerve status out of a scale from 1-10 is currently a 9.
Pfizer / BioNTech. Moderna; Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 37-year-old female patient (not pregnant) received bnt162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Fragrance allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "Pfizer / BioNTech. Moderna"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 included Paxlovid from 26Sep2023 to 01Oct2023. Clinical course: Severe pain, severe congestion, cough, headache, feeling bone chilling pain 7 days after positive Covid test. Had been getting a slow positive Covid test for a short time after completing Paxlovid then got an immediate positive test after symptoms began again and symptoms are much worse and unbearable.  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.; Sender's Comments: Vaccine efficacy can be affected by several factors such as the vaccine concentration, the kind of pathogen and the immune response mounted by the patient. Thus, the association between the event lack of effect (CoVID-19) with the suspect bnt162b2 (BNT162B2 NOS) cannot be fully excluded.
5/15/07 Child became irritable, right leg became swollen, hard and warm to touch - went to ER - dx with cellulitis - prescribed Clindamycin.
Intractable vomiting; diarrhea during 24 hours; severe weakness; This is a spontaneous report from a contactable consumer (patient).    An 82-year-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot Number: Lot9266, Expiry Date: Not Reported), via an unspecified route, administered in Left arm on 15Feb2021 (at the age of 82-year-old) at 13:00 as dose 2, single for covid-19 immunisation at hospital. The patient was not pregnant at time of vaccination. The patient was not pregnant at the time of vaccination. The patient medical history included breast cancer (Impossible to specify from breast cancer to arthritis and etc), and arthritis (Impossible to specify from breast cancer to arthritis and etc). The patient concomitant medications were not reported. The patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Lot Number: Not Reported, Expiry Date: Not Reported) via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient was not tested for COVID-19 since the vaccination. The patient was allergic to Opioids. On 20Feb2021, that is fifth day after the second vaccine dose, the patient experienced Intractable vomiting and diarrhea during 24 hours, severe weakness. On 21Feb2021 (Next day) vomiting stopped, no stomach on the third day. Severe weakness is continuing. The patient underwent lab tests and procedures which included blood pressure measurement: normal on an unspecified date, body temperature: normal on an unspecified date, oxygen saturation: no lower than 96 percentage on an unspecified date. The patient did not receive any treatment for the reported events. Outcome of the event intractable vomiting was recovered on 21Feb2021 and outcome for rest all events was recovering.  No follow-up attempts are needed. No further information is expected
This spontaneous report was received from a licensed vocational nurse regarding a patient of unknown demographics. There was no information about concurrent condition and historical medication. On 11-MAR-2015 patient was vaccinated with ZOSTAVAX (lot# K008880, expiry 09-SEP-2015) was inadvertently administered another dose of ZOSTAVAX (lot # L036454, expiry 22-DEC-2016) on 05-APR-2016. The outcome of event was unknown. Additional information has been requested.
Narrative:  Patient hospitalized for another reason (GI issue) but found to be COVID-19 positive - patient actually had no symptoms of COVID
Information has been received from a nurse practitioner concerning a patient who was vaccinated with a dose of varicella virus vaccine live. The NP reported in April 2004, the patient developed breakthrough chicken pox. Unspecified medical attention was sought. At the time of this report, the outcome was unknown. The NP also reported that another patient developed chicken pox after being vaccinated with varicella virus vaccine live (WAES0405USA00037). Additional information has been requested.
diabetic coma; my sugar skyrocketed/my blood sugar went up to over 600; This is a spontaneous report from a contactable consumer.  A 58-year-old female patient of received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection), dose 1 via an unspecified route of administration, administered in left arm on 25Mar2021 (Batch/Lot Number: ER2613) as dose 1, single (at the age of 58 years old), dose 2 via an unspecified route of administration, administered in right arm on 22Apr2021 (Batch/Lot Number: EW0158) as dose 2, single for COVID-19 immunisation.  Medical history included diabetes. Concomitant medications included metformin taken for diabetes mellitus, start and stop date were not reported.  The patient experienced that when she received her vaccine her sugar skyrocketed and asked why there is no warning for people, and that people are "leaving in ambulances" (from the vaccination site). Her blood sugar went to 600 for 3 weeks and that she was in a diabetic coma and know it was the vaccine, no doubt in her mind. Her blood sugar was never over 400 and she didn't do anything different and that this was scary. Treatment was they finally up her metformin (from 1000 a day to 3000 a day) after 3 weeks and gave her Glipizide 10 milligrams on the ER. The outcome of the event was recovered on an unspecified date in 2021.  No follow-up attempts are possible. No further information is expected.
Severe headache (almost causing nausea); mild flu symptoms. All symptoms lasted most of the day after vaccine booster.
2 separate areas continued for a total edema area covering 6 1/2cm increased 4 m <->, tender to touch, swollen to area.
Pt experienced brief dizziness and palor that resolved with laying supine with an ice pack for several minutes and sips of water. Slowly sat up and dangled to standing with no difficulties.
runny nose, scratchy throat,  cough, body aches, weakness, fever, and increase shortness of breath.
On 12/18/2020 when I woke up at 10am. The site area of the vaccine was sore, then my neck started hurting. When I went to the bathroom to view it, my right lymph node is swollen, and sore to touch. My lymph node is swollen on the same side I received the vaccine. It's still swollen today 12/22/20 and still sore to the touch. It was stated that reactions were to last 24-48hours, but this has lasted past then. No fever, no dizziness, and no nausea, just swelling in my neck.
I experienced a heart attack and was admitted to the hospital directly after arriving in the ER. The Cardiologist ordered a series of tests and I was diagnosed with Takotsubo Cardiomyopathy. A heart catherization procedure was performed to find out if I had any heart problems. I spent 3 days in the hospital and upon being released given prescriptions for medications to take along with Cardio Therapy and follows with the Cardiologists.
Had HIB/DTP approx 5PM 30MAR92 & later than evening spiked t102-103, lasting about 5 days; Fever tx w/APAP; rash was noted on 5APR, rash worse on 6APR; erythematous rash similar to urticarial rash; tx DPH;
the patient had fluid retention  all over her body; body was swelling; Received second dose 43 days after first dose; This spontaneous case was reported by a consumer and describes the occurrence of FLUID RETENTION (the patient had fluid retention  all over her body), SWELLING (body was swelling) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 43 days after first dose) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039B21A and 039B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FLUID RETENTION (the patient had fluid retention  all over her body), SWELLING (body was swelling) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 43 days after first dose). The patient was treated with FUROSEMIDE at an unspecified dose and frequency and NITROFURANTOIN at an unspecified dose and frequency. At the time of the report, FLUID RETENTION (the patient had fluid retention  all over her body), SWELLING (body was swelling) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 43 days after first dose) outcome was unknown.            No concomitant medications were not reported.
Ten year old female was given Pfizer Bivalent 12 and up vaccine in error. Only adverse effect was a sore arm after injection.
Injection site pain immediately after receiving vaccine; This is a spontaneous report from a non-contactable nurse, the patient. A 49-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration on 30Jul2021 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Jul2021, immediately after receiving the vaccine, the patient experienced injection site pain. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in 2021, the patient underwent antibody test and the result was unknown. The clinical outcome of the event injection site pain was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Body aches after 1st dose; Fatigue after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches after 1st dose) and FATIGUE (Fatigue after 1st dose) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014m20a and 008b212a) for COVID-19 vaccination.     The patient's past medical history included Anaphylactic reaction (Rag weed) and Anaphylactic reaction (Bees).   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN (Body aches after 1st dose) and FATIGUE (Fatigue after 1st dose). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, PAIN (Body aches after 1st dose) and FATIGUE (Fatigue after 1st dose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.     This case was linked to MODERNATX, INC.-MOD-2021-071381 (E2B Linked Report).; Sender's Comments:  MODERNATX, INC.-MOD-2021-071381:Second dose case
22APR93 mom called to ask about inject site; states hard knot @ site w/reddish rash & swelling 23APR93 low grade fever this AM; pain which prevented walking when first arose; swelling & redness have inc, rash has inc in diameter; MD seen;
Patient began experiencing urticaria about 24 hours later and has continued to experience dermatographia urticaria ever since involving the intertriginous zones predominantly but also on the torso, extremities. Did not mention it until his follow up 1/7/20. Has not tried any medication for the hives. They are gradually improving, less frequent and less severe.
breaking out on hives; This spontaneous case was reported by an other health care professional and describes the occurrence of URTICARIA (breaking out on hives) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced URTICARIA (breaking out on hives). At the time of the report, URTICARIA (breaking out on hives) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported. No Treatment medications were reported.
Guillain Barre Syndrome (acute inflammatory polyneuritis).  10/5/09 VAERS report received with MR attached. DOS 8/26-9/1/2009 with Principal dx:  Acute Inflammatory Demyelination. Polyneuropathy.  2' Dx:  HTN.  Tachycardia.  E.coli UTI. Pt presented after transfer from local hospital.  Pt presented to local hospital on 8/23/09 with c/o ascending numbness and weakness up to the arms with tingling in the cheeks and back pain.  PE (+) for decreased/absent reflexes throughout.  Ataxia in upper and lower extremities. Shuffling gait and proximal & distal weakness bilaterally. Normal sensation.  Dx with GBS. Tx IVIG. Developed increased BP and tachycardia during admission as well as E. coli UTI tx with abx.  Transferred for further rehab.  10/12/09 Outpatient, inpatient hospital records, DC summary received service dates 8/21/09 to 8/26/09. Assessment: Acute inflammatory demyelinating polyneuropathy progressive with weakness. Patient c/o migraine headache 4 days earlier. Two days prior to admission, patient developed jaw pain and tightness in the chest. Patient presents with numbness in feet and increased low back pain. Numbness in hands. Numbness in tongue, alteration of taste, facial discomfort. Balance is 'off' and unsteady with walking. Diffusely weak. Difficulty swallowing. Transferred to higher level facility.  10/12/09 PCP medical records received, service date 8/7/09. Assessment: Migraine with Aura. Patient c/o of increasing frequency of migraine headaches associated with nausea, auras, and tingling in face.   10/12/09 Additional hospital records received service dates 8/23/09 to 9/3/09. Supplemental information abstracted: Myalgia. Unable to perform activities of daily living.  10/12/09 ICD-9 Codes: 311 Depressive disorder, 592.0 Calculus of kidney, 575.11 Chronic Cholecystitis, 789.07 Abdominal pain generalized, 346.00 Migraine W/Aura
Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's pertinent medical history, drug allergies and concomitant medications were not reported. On 07-JUL-2016, the patient was vaccinated with PNEUMOVAX 23, (lot # L001311, dose and route were not reported) which expired on 06-JUL-2016. No adverse effects were reported. Additional information has been requested.
Patient had brief fainting spell after the flu vaccine was administered. She awoke and had patient laying down fully, Patient reported she hadn't eaten that evening so she was given  a cookie and water. Patient stayed for at least 15-20 minutes and reported doing ok and sweating had stopped, then she left. Patient declined an ambulance and was advised to see a doctor.
I didn't have any problems after the vaccination but 6 weeks I was diagnosed with Pulmonary emboli, I was coughing and short of breath and my oxygen dropped. I went to the clinic and I had and x-ray where I had a pulmonary Emboli. I was given Eliquis 10MG 2x daily for the first week, and now I'm on 5MG once a day. I am still having a significant cough and I have an appt again on 12/08/2021.
Patient went into unexpected and sudden cardiac arrest and died on 18Jun2021, prior to cardiac arrest patient was short of breath and was using increased oxygen (5L to maintain at 92%); Patient went into unexpected and sudden cardiac arrest and died on 18Jun2021, prior to cardiac arrest patient was short of breath and was using increased oxygen (5L to maintain at 92%); Patient went into unexpected and sudden cardiac arrest and died on 18Jun2021, prior to cardiac arrest patient was short of breath and was using increased oxygen (5L to maintain at 92%); Patient went into unexpected and sudden cardiac arrest and died on 18Jun2021, prior to cardiac arrest patient was short of breath and was using increased oxygen (5L to maintain at 92%); This is a spontaneous report from a contactable nurse. A 65-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via intramuscular route, administered in right arm on 17Jun2021 16:00 (age at vaccination: 65 years) as DOSE 1, SINGLE for covid-19 immunisation. The medical history included muscular sclerosis, myasthenia gravis, diabetes mellitus, multiple sclerosis and covid-19. The patient had covid prior vaccination. There were no known allergies. On 18Jun2021, the patient went into unexpected and sudden cardiac arrest and died, on 18Jun2021 22:00, prior to cardiac arrest patient was short of breath and was using increased oxygen (5l to maintain at 92%). The patient was attempted for resuscitation via CPR and EMS. On an unknown date, the patient underwent sars-cov-2 test which was positive. The patient received other medications received within 2 weeks of vaccination. The patient has not been tested for covid-19 since the vaccination. The patient died on 18Jun2021 due to cardiac arrest. An autopsy was not performed. The device timestamp was 04Jul2021.  Information on Lot/Batch information has been requested.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the events, cardiac arrest, Dyspnea, Death cannot be completely ruled out. The impact of this report on benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethic committees, and Investigators, as appropriate.; Reported Cause(s) of Death: Cardiac arrest
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, drug reactions, allergies or concomitant therapies provided. On 08-DEC-2016, the patient was vaccinated with incorrectly stored dose of M-M-R II (dose, frequency, route of administration were not reported, lot # M000768, expiration date 05-JAN-2018, status albumin: recombinant human albumin (rHA)). Concomitant medications were not reported. Administered vaccine experienced the temperature excursion of -14.4 Celsius degrees for 54 minutes. Data logger was involved. No adverse effects reported.    This is one of several reports received from the same reporter. Additional information is not expected, all information has already been obtained.; Sender's Comments: US-009507513-1611USA011831: US-009507513-1611USA004113: US-009507513-1705USA009742:
Fever and chills; Fever and chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An adult male patient received bnt162b2 (BNT162B2), administration date 2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid19 vaccine (Dose number: 1, prev dose product=COVID 19, prev dose brand unknown=True, prev dose brand name unknown=COVID19 Vaccine), for Covid-19 immunization; Covid19 vaccine (Dose number: 2, prev dose product=COVID 19, prev dose brand unknown=True, prev dose brand name unknown=COVID19 Vaccine), for Covid-19 immunization. The following information was reported: PYREXIA (non-serious), CHILLS (non-serious) all with onset Oct2021, outcome "recovered" (2021) and all described as "Fever and chills". It was unknown if therapeutic measures were taken as a result of pyrexia, chills.  Additional information: Facility type vaccine was Workplace clinic. It was unknown if the patient received other vaccine in four weeks. It was unknown if the patient had covid prior vaccination. The patient was not tested post vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a registered nurse concerning a female child who on 11-Feb-2004 was vaccinated in the left left with a dose of varicella virus vaccine live (lot #644789/0329N). The nurse reported that on 11-Feb-2004, the patient experienced a local site reaction and developed a 3/4 centimeter red area at the injection site. No treatment was needed. The reporter has requested a lot check. The records of testing prior to release of this lot have been checked by quality assurance and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. Additional information has been requested. The nurse also reported that the patient's brother experienced a similar reaction after therapy with varicella virus vaccine live  (WAES #0402USA01433, 0402USA01540, and 0402USA01541). The nurse reported another child who experienced a similar reaction after therapy with varicella virus vaccine live (WAES #0402USA01546). It was noted that the triplets had the worse reaction. The nurse also reported two other children who experienced a similar reaction after therapy with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (WAES  #0402USA01554 and 0402USA01555).
Rectal temp to 101.4 in child under 12 weeks. ER visit required.
Vax administered 8/8/02. On 8/9/02 pt had fever 104 degrees, malaise, myalgias, dizziness, nausea, high neutrophil count, normal WBC count, negative blood cultures. Treated with Tylenol. Symptoms resolved.